Information for Patients
Understand How Modern Liquid Biopsy Tests Can Support and Improve Your Cancer Treatment
Your Health in Focus
Our Vista ctDNA tests allow precise monitoring of your cancer using just a simple blood draw - no surgical procedures or invasive biopsies required.
What is Liquid Biopsy?
A liquid biopsy is a modern diagnostic method that detects tumor DNA from a blood sample. Cancer cells continuously release small fragments of DNA (called circulating tumor DNA, or ctDNA) into the bloodstream. With highly sensitive analytical methods, these fragments can be detected and analyzed - offering valuable information about your cancer without the need for surgery. This approach also supports minimal residual disease MRD detection, helping doctors understand how much, if any, cancer remains after treatment.
High Sensitivity for Early and Accurate Results
Our tests offer very high sensitivity, detecting even minute traces of tumor DNA in the blood. This makes it possible to evaluate treatment success or relapse earlier than with conventional imaging techniques.
If your doctor tells you that your result is „minimal residual disease negative,“ it means that no
remaining cancer DNA was detected in your blood at the time of testing - a strong indicator of a
favorable response to therapy.
(Learn more below about the
minimal residual disease negative meaning and how your
oncologist interprets this result.)
By Medical Order Only
Important: Our tests are performed
only on the order of your treating physician.
Please discuss liquid biopsy options
with your oncologist or contact us directly. We'll gladly provide information and can refer you to a
qualified doctor familiar with ctDNA testing and interpretation.
Our Tests for Patients
LymphoVista - B-Cell Lymphomas
Test for a wide range of B-cell lymphomas including DLBCL, follicular, mantle cell, Burkitt, and CNS lymphomas. Enables precise monitoring of treatment response and minimal residual disease status.
LymphoVista HL - Hodgkin Lymphoma
A specialized test for Hodgkin lymphoma with a dedicated gene spectrum, supporting personalized therapy decisions and monitoring.
CancerVista - Solid Tumors
Our test for solid tumors is under development. Once available, it will allow ctDNA-based detection and monitoring for cancers such as lung, breast, colorectal, prostate, and others.
Your Benefits
Gentle Examination
Just a simple blood draw - minimally invasive and painless
Regular Monitoring
Frequent testing enables continuous tracking of therapy success.
Precise Results
Detects even tiny amounts of tumor DNA in the bloodstream.
Early Detection
Relapses can be identified early, often before symptoms appear.
Your Path to Liquid Biopsy
Consultation with Your Doctor
Your oncologist will discuss whether a liquid biopsy is appropriate for your specific condition and what
information the test can provide.
You can also contact us directly - we’re happy to answer your questions
and help connect you with a specialist.
Blood Draw
Approximately 20 ml of blood is collected at your clinic or practice just like a routine blood test. The sample is then sent to our certified laboratory.
Laboratory Analysis
Our experts analyze your blood using cutting-edge ctDNA methods. These identify tumor-specific genetic material and evaluate whether cancer DNA remains in your bloodstream.
Results Discussion
Within about 2-4 weeks, your physician receives a detailed report securely via encrypted email. Your doctor will review the findings with you and explain what they mean for your ongoing treatment. Understanding your minimal residual disease negative meaning - if no tumor DNA is detected - helps assess treatment success and guide your next steps.
Talk to Your Doctor
Ask your oncologist about liquid biopsy options for your cancer monitoring. Or reach out to us - we’re happy to guide you and your physician through the process.
Get in Touch